Table 1:
Baseline data for trial participants
| Characteristic | Placebo or zolendronate dose; mean ± SD* | |||
|---|---|---|---|---|
| Placebo n = 34 |
1 mg n = 39 |
2.5 mg n = 38 |
5 mg n = 41 |
|
| Age, yr | 63 ± 8 | 64 ± 8 | 67 ± 9 | 66 ± 8 |
| Weight, kg | 67 ± 13 | 68 ± 9 | 66 ± 10 | 66 ± 12 |
| Current smoker, no. (%) | 0 | 0 | 1 (3) | 0 |
| Calcium intake, mg/d | 956 ± 327 | 965 ± 336 | 881 ± 411 | 852 ± 522 |
| Serum 25-hydroxyvitamin D, nmol/L | 74 ± 19 | 71 ± 17 | 67 ± 19 | 71 ± 20 |
| Fracture during adulthood, no. (%)† | 8 (24) | 18 (46) | 8 (21) | 12 (29) |
| Lumbar spine BMD, g/cm2 | 1.02 ± 0.10 | 1.02 ± 0.08 | 1.03 ± 0.11 | 1.05 ± 0.12 |
| T score | −1.4 ± 0.8 | −1.3 ± 0.7 | −1.2 ± 0.9 | −1.1 ± 1.0 |
| Total hip BMD, g/cm2 | 0.87 ± 0.07 | 0.85 ± 0.08 | 0.84 ± 0.06 | 0.84 ± 0.09 |
| T score | −1.1 ± 0.6 | −1.2 ± 0.7 | −1.3 ± 0.5 | −1.3 ± 0.7 |
| Total body BMD, g/cm2 | 1.08 ± 0.06 | 1.06 ± 0.06 | 1.07 ± 0.06 | 1.06 ± 0.05 |
| T score | −0.6 ± 0.7 | −0.8 ± 0.7 | −0.7 ± 0.8 | −0.8 ± 0.7 |
| P1NP, μg/L | 55 ± 23 | 61 ± 21 | 57 ± 16 | 58 ± 18 |
| β-CTX, ng/L | 460 ± 210 | 470 ± 200 | 480 ± 180 | 460 ± 220 |
Note: β-CTX = β-C-terminal telopeptide of type I collagen, BMD = bone mineral density, P1NP = procollagen type 1 N-terminal propeptide, SD = standard deviation.
*
Except where indicated otherwise.
†
Excluding motor vehicle crashes.